Skip to search formSkip to main contentSkip to account menu

indium In 111 monoclonal antibody MN-14

Known as: In111 MOAB MN-14, In 111 monoclonal antibody MN-14, In 111 MOAB MN-14 
A radioimmunoconjugate of a murine monoclonal antibody, MoAb MN-14, labeled with indium 111 (In-111). MoAb Lym-1 recognizes an epitope of… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.
BACKGROUND Monoclonal antibodies (MAbs) against carcinoembryonic antigen (CEA) have been recognized as targeting agents for… 
1999
1999
Importance of timing of radioimmunotherapy after granulocyte colony-stimulating factor administration for peripheral blood stem cell harvest.
Nine radioimmunotherapy (RAIT)-naive patients with medullary thyroid cancer received high doses of 131I-MN-14 F(ab)2 anti… 
1997
1997
Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.
OBJECTIVES Epithelial ovarian cancer (EOC) is known to produce carcinoembryonic antigen (CEA), and the plasma CEA level is… 
1997
1997
Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody.
Advanced chemotherapy-resistant ovarian cancer has a poor prognosis, thus requiring new therapeutic modalities. A complete… 
1996
1996
Clinical evaluation of tumor targeting with the anticarcinoembryonic antigen murine monoclonal antibody fragment, MN‐14 F(ab)2
The initial clinical experience with the second‐generation, high‐affinity, MN‐14 immunoglobulin (IgG) anticarcinoembryonic… 
1995
1995
Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen.
The targeting potential of 131I-labeled NP-4 and MN-14 anti-CEA (carcinoembryonic antigen) monoclonal antibodies (MAbs) was… 
1995
1995
Improved experimental cancer therapy by radioantibody dose intensification as a result of syngeneic bone marrow transplantation.
Myelosuppressive toxicity is dose-limiting for radioimmunotherapy. We have reported on the use of cytokine intervention (rhIL-1… 
1990
1990
Comparison of tumor targeting in nude mice by murine monoclonal antibodies directed against different human colorectal cancer antigens.
Tumor targeting of five radioiodinated murine monoclonal antibodies (MAbs) directed against human colorectal cancer were studied… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)